Bezlotoxumab Injection [Zinplava]
Pre-clinicalCompleted 0 watching 0 views this week💤 Quiet
23
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Clostridium Difficile Infection
Conditions
Clostridium Difficile Infection
Trial Timeline
Oct 1, 2019 → Oct 28, 2022
NCT ID
NCT04075422About Bezlotoxumab Injection [Zinplava]
Bezlotoxumab Injection [Zinplava] is a pre-clinical stage product being developed by Merck for Clostridium Difficile Infection. The current trial status is completed. This product is registered under clinical trial identifier NCT04075422. Target conditions include Clostridium Difficile Infection.
Hype Score Breakdown
Clinical
5
Activity
2
Company
10
Novelty
2
Community
1
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04075422 | Pre-clinical | Completed |
Competing Products
20 competing products in Clostridium Difficile Infection